Publication: Rational design of novel sirtuin 1 activators via structure-activity insights from application of QSAR modeling
Issued Date
2019-01-01
Resource Type
ISSN
16112156
Other identifier(s)
2-s2.0-85066092980
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
EXCLI Journal. Vol.18, (2019), 207-222
Suggested Citation
Reny Pratiwi, Veda Prachayasittikul, Supaluk Prachayasittikul, Chanin Nantasenamat Rational design of novel sirtuin 1 activators via structure-activity insights from application of QSAR modeling. EXCLI Journal. Vol.18, (2019), 207-222. doi:10.17179/excli2019-1274 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/49869
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Rational design of novel sirtuin 1 activators via structure-activity insights from application of QSAR modeling
Other Contributor(s)
Abstract
© 2019, Leibniz Research Centre for Working Environment and Human Factors. All rights reserved. Sirtuin 1 (SIRT1) enzyme regulates major cell activities, and its activation offers lucrative therapeutic potentials for aging diseases including Alzheimer’s disease (AD). Regarding the global aging society, continual attention has been given to various chemical scaffolds as a source for the discovery of novel SIRT1 activators since the discovery of the pioneer activator, resveratrol. Understanding structure-activity relationship (SAR) is essential for screening, designing as well as improving the properties of drugs. In this study, an in silico approach based on quantitative structure-activity relationship (QSAR) modeling, was employed for understanding the SAR of currently available SIRT1 fused-aromatic activators (i.e., imidazothiazole, oxazolopyridine, and azabenzimidazole analogs). Three QSAR models constructed using multiple linear regression (MLR) provided good predictive performance (R2LOOCV = 0.729-0.863 and RMSELOOCV = 0.165-0.325). An additional novel set of 181 structurally modified compounds were rationally designed according to key descriptors deduced from the QSAR findings and their SIRT1 activities were predicted using the constructed models. In overview, the study provides insightful SAR findings of currently available SIRT1 activators that would be useful for guiding the rational design, screening, and development of further potent SIRT1 activators for managing age-related clinical conditions. A series of promising compounds as well as important scaffolds and molecular properties for potent SIRT1 activator were highlighted. This study demonstrated the efficacious role of QSAR-driven structural modification for the rational design of novel leads.